$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information
SOURCE Kalorama Information
ARLINGTON, Va., July 9, 2025 /PRNewswire/ -- Kalorama Information, a leading authority in healthcare market research, announces the release of its new report, Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024–2030). The study reveals that the global market for cell and gene therapy (CGT) is poised to surge from $14.1 billion in 2024 to more than double by 2030, driven by scientific advancements, regional market expansion, and next-generation product approvals.
"Novartis is currently leading the cell and gene therapy market with sales generated from its oncology CAR-T therapy Kymriah, its acquired gene therapy for muscular atrophy Zolgensma, and Leqvio. Gilead Sciences, with Yescarta and Tecartus, is the second largest provider of cell and gene therapy, specializing in oncology CAR-T therapy," said Justin Saeks, Senior Analyst at Kalorama and the report's author.
As oncology and rare genetic diseases continue to dominate the CGT landscape, new growth is emerging in therapeutic areas like musculoskeletal, dermatology, and cardiovascular applications. While oncology drives revenue in North America, neurology leads in Europe, underscoring distinct regional dynamics.
The report offers detailed market estimates, regional forecasts, and competitive insights, and highlights:
- 15%+ CAGR in oncology led by CAR T-cell therapies and lymphoma treatments
- 17% market share held by Novartis, followed by Kite/Gilead at 14%
- Key shifts in RNA/antisense therapy adoption, with regulatory ambiguity on mRNA's classification across regions
The CGT industry now faces its next major inflection point: the industrialization and standardization of manufacturing processes, where automation and closed systems are becoming imperative. Business leaders are also innovating new models to address cost, access, and scalability.
Why This Matters
With over 100+ tables and charts, this report provides strategic guidance for:
- R&D and pipeline teams evaluating target diseases and emerging competitors
- Corporate development leaders exploring M&A and early-stage investment targets
- Marketers and regulatory professionals planning product launches and global expansion
The report is essential reading for executives in biopharma, biotech startups, CDMOs, life sciences investment, and healthcare strategy.
Download the Report
Purchase or learn more about the report here:
Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
Media Contact
Alisa Alvich
Marketing Director
[email protected]
Sales & Research Inquiries
Sheri Davie
Sales Director, Science and Medicine Group
[email protected]
View original content to download multimedia:
©PR Newswire. All Rights Reserved.
Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
